{"id":46594,"date":"2022-07-26T20:03:00","date_gmt":"2022-07-26T18:03:00","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/aurinia-pharmaceuticals-notification-regarding-inter-partes-patent-review\/"},"modified":"2022-07-26T20:03:00","modified_gmt":"2022-07-26T18:03:00","slug":"aurinia-pharmaceuticals-notification-regarding-inter-partes-patent-review","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/aurinia-pharmaceuticals-notification-regarding-inter-partes-patent-review\/","title":{"rendered":"Aurinia Pharmaceuticals Notification Regarding Inter Partes Patent Review"},"content":{"rendered":"
\n

VICTORIA, British Columbia and ROCKVILLE, Md.–(BUSINESS WIRE)–Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (\u201cAurinia\u201d or the \u201cCompany\u201d) today received notice regarding the U.S. Patent Office (USPTO) Patent Trial and Appeal Board (PTAB) decision to institute trial on the Inter Partes<\/i> review (\u201cIPR\u201d) filed by Sun Pharmaceuticals, directed at U.S. Patent No. 10,286,036. This patent is related to the LUPKYNIS\u00ae <\/sup>dosing protocol for lupus nephritis.\n<\/p>\n

<\/a><\/p>\n

\n\u201cWhile this decision is disappointing, as we have stated from the start of his process, we will vigorously defend this patent,\u201d said Peter Greenleaf, President and CEO, Aurinia Pharmaceuticals. \u201cThis patent already had significant review at the USPTO before being approved as being a valid patent by that office and we are fully prepared to continue legal proceedings to protect our intellectual property.\u201d\n<\/p>\n

\nPatent No. 10,286,036 was issued to Aurinia in support of the unique eGFR pharmacodynamic dosing protocol used within the Company\u2019s clinical trials, and extends patent protection for LUPKYNIS to 2037. Regardless of the final outcomes of the IPR, the Company has filed a standard form patent term extension for its existing composition of matter patent, which, if granted, would extend the term of that patent by 5 years to October 2027. A determination on patentability, relative to the IPR, is expected on or prior to July 26, 2023.\n<\/p>\n

\nAbout Aurinia<\/b>\n<\/p>\n

\nAurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. In January 2021, the Company introduced LUPKYNIS\u00ae (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis (LN). The Company\u2019s head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor and Corporate<\/b>
DeDe Sheel, VP, Investor Relations<\/b>
aurinia@westwicke.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

VICTORIA, British Columbia and ROCKVILLE, Md.–(BUSINESS WIRE)–Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (\u201cAurinia\u201d or the \u201cCompany\u201d) today received notice regarding the U.S. Patent Office (USPTO) Patent Trial and Appeal Board (PTAB) decision to institute trial on the Inter Partes review (\u201cIPR\u201d) filed by Sun Pharmaceuticals, directed at U.S. Patent No. 10,286,036. This patent is related to … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46594","6":"format-standard","7":"category-industry"},"yoast_head":"\nAurinia Pharmaceuticals Notification Regarding Inter Partes Patent Review - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/aurinia-pharmaceuticals-notification-regarding-inter-partes-patent-review\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aurinia Pharmaceuticals Notification Regarding Inter Partes Patent Review - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"VICTORIA, British Columbia and ROCKVILLE, Md.–(BUSINESS WIRE)–Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (\u201cAurinia\u201d or the \u201cCompany\u201d) today received notice regarding the U.S. Patent Office (USPTO) Patent Trial and Appeal Board (PTAB) decision to institute trial on the Inter Partes review (\u201cIPR\u201d) filed by Sun Pharmaceuticals, directed at U.S. Patent No. 10,286,036. This patent is related to ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/aurinia-pharmaceuticals-notification-regarding-inter-partes-patent-review\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-26T18:03:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220726006036\/en\/787478\/21\/Aurinia-Logo-RBG-031620-v01.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aurinia-pharmaceuticals-notification-regarding-inter-partes-patent-review\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aurinia-pharmaceuticals-notification-regarding-inter-partes-patent-review\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Aurinia Pharmaceuticals Notification Regarding Inter Partes Patent Review\",\"datePublished\":\"2022-07-26T18:03:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aurinia-pharmaceuticals-notification-regarding-inter-partes-patent-review\\\/\"},\"wordCount\":313,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aurinia-pharmaceuticals-notification-regarding-inter-partes-patent-review\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220726006036\\\/en\\\/787478\\\/21\\\/Aurinia-Logo-RBG-031620-v01.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aurinia-pharmaceuticals-notification-regarding-inter-partes-patent-review\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aurinia-pharmaceuticals-notification-regarding-inter-partes-patent-review\\\/\",\"name\":\"Aurinia Pharmaceuticals Notification Regarding Inter Partes Patent Review - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aurinia-pharmaceuticals-notification-regarding-inter-partes-patent-review\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aurinia-pharmaceuticals-notification-regarding-inter-partes-patent-review\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220726006036\\\/en\\\/787478\\\/21\\\/Aurinia-Logo-RBG-031620-v01.jpg\",\"datePublished\":\"2022-07-26T18:03:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aurinia-pharmaceuticals-notification-regarding-inter-partes-patent-review\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aurinia-pharmaceuticals-notification-regarding-inter-partes-patent-review\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aurinia-pharmaceuticals-notification-regarding-inter-partes-patent-review\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220726006036\\\/en\\\/787478\\\/21\\\/Aurinia-Logo-RBG-031620-v01.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220726006036\\\/en\\\/787478\\\/21\\\/Aurinia-Logo-RBG-031620-v01.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aurinia-pharmaceuticals-notification-regarding-inter-partes-patent-review\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aurinia Pharmaceuticals Notification Regarding Inter Partes Patent Review\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aurinia Pharmaceuticals Notification Regarding Inter Partes Patent Review - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/aurinia-pharmaceuticals-notification-regarding-inter-partes-patent-review\/","og_locale":"en_US","og_type":"article","og_title":"Aurinia Pharmaceuticals Notification Regarding Inter Partes Patent Review - Pharma Trend","og_description":"VICTORIA, British Columbia and ROCKVILLE, Md.–(BUSINESS WIRE)–Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (\u201cAurinia\u201d or the \u201cCompany\u201d) today received notice regarding the U.S. Patent Office (USPTO) Patent Trial and Appeal Board (PTAB) decision to institute trial on the Inter Partes review (\u201cIPR\u201d) filed by Sun Pharmaceuticals, directed at U.S. Patent No. 10,286,036. This patent is related to ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/aurinia-pharmaceuticals-notification-regarding-inter-partes-patent-review\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-26T18:03:00+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220726006036\/en\/787478\/21\/Aurinia-Logo-RBG-031620-v01.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/aurinia-pharmaceuticals-notification-regarding-inter-partes-patent-review\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/aurinia-pharmaceuticals-notification-regarding-inter-partes-patent-review\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Aurinia Pharmaceuticals Notification Regarding Inter Partes Patent Review","datePublished":"2022-07-26T18:03:00+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/aurinia-pharmaceuticals-notification-regarding-inter-partes-patent-review\/"},"wordCount":313,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/aurinia-pharmaceuticals-notification-regarding-inter-partes-patent-review\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220726006036\/en\/787478\/21\/Aurinia-Logo-RBG-031620-v01.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/aurinia-pharmaceuticals-notification-regarding-inter-partes-patent-review\/","url":"https:\/\/pharma-trend.com\/en\/aurinia-pharmaceuticals-notification-regarding-inter-partes-patent-review\/","name":"Aurinia Pharmaceuticals Notification Regarding Inter Partes Patent Review - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/aurinia-pharmaceuticals-notification-regarding-inter-partes-patent-review\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/aurinia-pharmaceuticals-notification-regarding-inter-partes-patent-review\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220726006036\/en\/787478\/21\/Aurinia-Logo-RBG-031620-v01.jpg","datePublished":"2022-07-26T18:03:00+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/aurinia-pharmaceuticals-notification-regarding-inter-partes-patent-review\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/aurinia-pharmaceuticals-notification-regarding-inter-partes-patent-review\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/aurinia-pharmaceuticals-notification-regarding-inter-partes-patent-review\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220726006036\/en\/787478\/21\/Aurinia-Logo-RBG-031620-v01.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220726006036\/en\/787478\/21\/Aurinia-Logo-RBG-031620-v01.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/aurinia-pharmaceuticals-notification-regarding-inter-partes-patent-review\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Aurinia Pharmaceuticals Notification Regarding Inter Partes Patent Review"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46594","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46594"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46594\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46594"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46594"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46594"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}